April 17, 2020 Posted By Categories Gary Schwitzer is the founder of HealthNewsReview.org and has been its publisher for 14 years. He tweets as @garyschwitzer or as @HealthNewsRevu This is what STAT reported in what they labeled an “Exclusive” last evening. Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment… Read More »
(Reuters) – Nearly half of lymphoma patients treated with Gilead Sciences Inc’s Yescarta were alive at least three years after a one-time infusion of the CAR-T cell therapy, according to data presented on Saturday. FILE PHOTO: A Gilead Sciences, Inc. logo is seen outside the company headquarters in Foster City, California, U.S. May 1, 2018.… Read More »
Back in May, new Gilead Sciences CEO Daniel O’Day said he’d be looking for a CEO for Gilead’s Kite unit. And he’s found his pick. Thursday, the Big Biotech said it would bring on Eli Lilly executive Christi Shaw to run the cell therapy company, which Gilead snagged in 2017 for $ 12 billion. She’ll… Read More »
With Gilead’s CEO on the way out and revenues tumbling, the company needs a leader who can pump up cancer sales. And it may have found just that in the ranks of the world’s biggest cancer drug maker. The Big Biotech has poached longtime Roche exec Daniel O’Day, who’ll take the helm at Gilead on… Read More »
SAN DIEGO (Reuters) – Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc’s Yescarta were still responding to the cell therapy after at least two years of follow-up, the company said on Sunday. FILE PHOTO: A Gilead Sciences, Inc. office is shown in Foster City, California, U.S. May 1,… Read More »